Bristol-Myers Squibb has tightened rules on the way its sales representatives work with doctors in China after a $14m settlement over bribery allegations.
百時美施貴寶(Bristol-Myers Squibb,簡稱BMS)收緊了對其銷售代表與中國醫生打交道方式的規范,此前該公司支付1400萬美元了結賄賂指控。
您已閱讀8%(232字),剩余92%(2742字)包含更多重要信息,訂閱以繼續探索完整內容,并享受更多專屬服務。